Carbin 1990.

Study characteristics
Methods	Study design: parallel‐group randomized trial Study dates: not available Setting: outpatient, multicenter, international Country: Sweden/Denmark
Participants	Inclusion criteria: Men between 50 and 80 years old Presence of BPH Prostate examination Acid phosphatase determination Exclusion criteria: need for surgery or residual urine > 300 mL Sample size: 55 Age (years): Group 1 mean (SD): 62.0 (± 6.7) Group 2 mean (SD): 61.2 (± 5.8) IPSS/AUASI score (baseline): Group 1 mean (SD): 6.8 (± 1.4) Group 2 mean (SD): 6.6 (± 1.3) Prostate size: not available
Interventions	Group 1 (n = 26): Curbicin contains 160 mg of standardized extract PS6 from Cucurbita pepo L. seeds (80 mg) and Sabal serrulata fruits (80 mg). The tablets were swallowed whole in a dose of 2 tablets 3 times a day (possibly 3 months). Group 2 (n = 27): placebo tables were identical in smell, consistency, shape, color, and taste to the active compound (possibly 3 months) Co‐interventions: none
Outcomes	Adverse events How measured: not described (they were reported in a sentence: “No untoward side effects were reported”) Time points measured: not available (possibly 3 months) Time points reported: not available Subgroups: none Other outcomes measured in the trial: Qmax, micturition time, residual volume, diurnal frequency, nocturnal frequency, and duration of illness. Subjective symptoms such as dysuria and global assessment of the therapy were evaluated with a scale: much better, better, the same, worse.
Notes	Funding sources: not available Declarations of interest: not available